Cancers, Vol. 11, Pages 1834: Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Cancers, Vol. 11, Pages 1834: Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia Cancers doi: 10.3390/cancers11121834 Authors: Puła Gołos Górniak Jamroziak Ibrutinib is the first Bruton’s tyrosine kinase (BTK) inhibitor, which showed significant clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients regardless of cytogenetic risk factors. Recent results of phase III clinical trials in treatment-naïve CLL patients shift the importance of the agent to frontline therapy. Nevertheless, beside its clinical efficacy, ibrutinib possesses some off-target activity resulting in ibrutinib-characteristic adverse events including bleeding diathesis and arrhythmias. Furthermore, acquired and primary resistance to the drug have been described. As the use of ibrutinib in clinical practice increases, the problem of resistance is becoming apparent, and new methods of overcoming this clinical problem arise. In this review, we summarize the mechanisms of BTK inhibitors’ resistance and discuss the post-ibrutinib treatment options.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research